Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis

To assess safety outcomes for the induction therapies alemtuzumab and autologous hematopoietic stem cell transplantation (AHSCT) compared to noninduction disease-modifying therapies. We performed a population-based cohort study linking the Swedish Multiple Sclerosis Register to national health care...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neurology 2021-03, Vol.96 (11), p.e1574-e1584
Hauptverfasser:	Alping, Peter, Burman, Joachim, Lycke, Jan, Frisell, Thomas, Piehl, Fredrik
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Alemtuzumab - adverse effects Cohort Studies Female Hematopoietic Stem Cell Transplantation - adverse effects Humans Immunologic Factors - adverse effects Infections - epidemiology Infections - etiology Male Middle Aged Multiple Sclerosis, Relapsing-Remitting - therapy Neurosciences Neurosciences & Neurology Neurovetenskaper Registries Sweden - epidemiology Thyroid Diseases - chemically induced Thyroid Diseases - epidemiology Transplantation, Autologous - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!